Mobilization of arachidonic acid in thrombin-stimulated human platelets.
In the present work we investigated the effect of serine esterase inhibitors such as 2-nitro-4-carboxyphenyl N,N-diphenylcarbamate (NCDC) and phenylmethylsulfonyl fluoride (PMSF), as well as the effect of mepacrine on thrombin-induced mobilization of arachidonic acid (AA) in human platelets. The inhibitor NCDC (0.6 mM) completely abolished the thrombin-induced activation of phospholipase C, phospholipase A2, and transacylase enzymes, whereas the pretreatment of platelets with PMSF (2 mM) resulted in a highly selective inhibition of phospholipase A2 and transacylase activities, with no marked effect on thrombin-induced activation of phospholipase C. The thrombin-induced release of [3H]AA from phosphatidylcholine and phosphatidylinositol was reduced by 90 and 56%, respectively, in the presence of PMSF. This inhibitor also caused a parallel inhibition in the accumulation of [3H]AA (85%) with little effect on thrombin-induced formation of [3H]phosphatidic acid (5%), whereas mepacrine (0.4 mM) caused a selective inhibition of phospholipase A2 and transacylase activities with concomitant stimulation of [3H]phosphatidic acid formation in intact human platelets. These results demonstrate that NCDC and PMSF (serine esterase inhibitors) do not affect agonist-induced activation of phospholipases that mobilize arachidonic acid through a common site. Our results further demonstrate that the inhibition of [3H]AA release observed in the presence of NCDC, PMSF, and mepacrine is primarily due to their direct effects on enzyme activities, rather than due to their indirect effects through formation of complexes between inhibitors and membrane phospholipids. Based upon these results, we also conclude that the combined hydrolysis of phosphatidylcholine and phosphatidylinositol by phospholipase A2 serves as a major source for eicosanoid biosynthesis in thrombin-stimulated human platelets.
Mahadevappa
V G
VG
Department of Nutritional Sciences, University of Guelph, Ont., Canada.
Sicilia
F
F
D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000097:blood* / Q000378:metabolism; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D002219:Carbamates / Q000494:pharmacology; D004950:Esterases / Q000037:antagonists & inhibitors; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006801:Humans; D066298:In Vitro Techniques; D048448:Phenylcarbamates; D010664:Phenylmethylsulfonyl Fluoride / Q000494:pharmacology; D010712:Phosphatidic Acids / Q000097:blood; D010713:Phosphatidylcholines / Q000097:blood; D010741:Phospholipases A / Q000037:antagonists & inhibitors; D054467:Phospholipases A2; D010743:Phospholipids / Q000097:blood; D011796:Quinacrine / Q000494:pharmacology; D013917:Thrombin / Q000494:pharmacology*
D001095:Arachidonic Acids; D002219:Carbamates; D005230:Fatty Acids, Nonesterified; D048448:Phenylcarbamates; D010712:Phosphatidic Acids; D010713:Phosphatidylcholines; D010743:Phospholipids; C025508:2-nitro-4-carboxyphenyl-N,N-diphenylcarbamate; D016718:Arachidonic Acid; D010664:Phenylmethylsulfonyl Fluoride; D004950:Esterases; C022635:serine esterase; D010741:Phospholipases A; D054467:Phospholipases A2; D013917:Thrombin; D011796:Quinacrine